WO2013131010A3 - Function of chemokine receptor ccr8 in melanoma metastasis - Google Patents
Function of chemokine receptor ccr8 in melanoma metastasis Download PDFInfo
- Publication number
- WO2013131010A3 WO2013131010A3 PCT/US2013/028683 US2013028683W WO2013131010A3 WO 2013131010 A3 WO2013131010 A3 WO 2013131010A3 US 2013028683 W US2013028683 W US 2013028683W WO 2013131010 A3 WO2013131010 A3 WO 2013131010A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- function
- ccr8
- chemokine receptor
- melanoma metastasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention provides a method of treating a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby treat the subject. This invention also provides a method of reducing, or reducing the likelihood of, metastases in a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby reduce, or reduce the likelihood of, metastases in the subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606169P | 2012-03-02 | 2012-03-02 | |
US61/606,169 | 2012-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013131010A2 WO2013131010A2 (en) | 2013-09-06 |
WO2013131010A3 true WO2013131010A3 (en) | 2013-11-14 |
Family
ID=49083467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/028683 WO2013131010A2 (en) | 2012-03-02 | 2013-03-01 | Function of chemokine receptor ccr8 in melanoma metastasis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013131010A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048567A1 (en) * | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Spirocyclic ebi2 modulators |
US10087259B1 (en) * | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
CN107849017B (en) | 2015-07-31 | 2021-03-30 | 辉瑞公司 | 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAGL inhibitors |
JP7358047B2 (en) * | 2016-05-16 | 2023-10-10 | チェックマブ エス.アール.エル. | Markers selectively deregulated in tumor-infiltrating regulatory T cells |
BR112019014688A2 (en) | 2017-01-20 | 2020-02-18 | Pfizer Inc. | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AS MAGL INHIBITORS |
WO2018134698A1 (en) | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
DK3616720T3 (en) * | 2017-03-29 | 2021-03-29 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT |
CN108727400B (en) * | 2017-05-24 | 2021-07-09 | 四川晶华生物科技有限公司 | Compound for treating tumor |
JP6894086B2 (en) * | 2018-12-27 | 2021-06-23 | 塩野義製薬株式会社 | New anti-CCR8 antibody |
CN114929278A (en) | 2020-01-06 | 2022-08-19 | 瓦西尼斯公司 | anti-CCR 8 antibodies and uses thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
KR20230035602A (en) * | 2020-07-03 | 2023-03-14 | 난징 이뮤노파지 바이오테크 코., 엘티디. | Methods and compositions for targeting Tregs with CCR8 inhibitors |
EP4267618A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Non-blocking human ccr8 binders |
KR20230142745A (en) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | CDK2 inhibitors and methods of their use |
MX2023015436A (en) | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Cdk2 inhibitors and methods of using the same. |
WO2024115549A1 (en) | 2022-11-30 | 2024-06-06 | Idorsia Pharmaceuticals Ltd | Aryl- and heteroaryl-sulfonamide derivatives as ccr8 modulators |
WO2024133292A1 (en) * | 2022-12-19 | 2024-06-27 | Katholieke Universiteit Leuven | Novel ccr8 antagonists |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090214533A1 (en) * | 2006-08-17 | 2009-08-27 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
US20110053969A1 (en) * | 2005-04-04 | 2011-03-03 | Astrazeneca Ab | Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases |
US20110150982A1 (en) * | 2002-11-15 | 2011-06-23 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
-
2013
- 2013-03-01 WO PCT/US2013/028683 patent/WO2013131010A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110150982A1 (en) * | 2002-11-15 | 2011-06-23 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
US20110053969A1 (en) * | 2005-04-04 | 2011-03-03 | Astrazeneca Ab | Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases |
US20090214533A1 (en) * | 2006-08-17 | 2009-08-27 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
Also Published As
Publication number | Publication date |
---|---|
WO2013131010A2 (en) | 2013-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013131010A3 (en) | Function of chemokine receptor ccr8 in melanoma metastasis | |
MX2018006973A (en) | Humanized anti-cd73 antibodies. | |
MX2017016502A (en) | Antibodies to cd40 with enhanced agonist activity. | |
MX2021002406A (en) | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor. | |
EP3736294A3 (en) | Cd73 blockade | |
MX347164B (en) | Anti il-36r antibodies. | |
MX2016007885A (en) | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody. | |
WO2012099973A3 (en) | Compositions and methods for treating cancer | |
MX2014011134A (en) | Carbamate compounds and of making and using same. | |
MX361242B (en) | Methods of treating immune disorders with single domain antibodies against tnf-alpha. | |
EA201400625A1 (en) | ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION | |
WO2012061537A3 (en) | Methods for treating hair loss disorders | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
WO2014089169A3 (en) | Immunotherapy with binding agents | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
WO2011130347A3 (en) | Methods for enhancing axonal regeneration | |
MX2014004074A (en) | Methods of treating liver conditions using notch2 antagonists. | |
WO2012094328A3 (en) | Hedgehog antagonists having zinc binding moieties | |
WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
WO2013090635A3 (en) | Composition and method for the diagnosis and treatment of iron-related disorders | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. | |
NZ722600A (en) | Methods of treating mild brain injury | |
WO2013106460A3 (en) | Compositions and methods for treating malignant astrocytomas | |
WO2014097318A3 (en) | Agents for eliminating tumour-initiating cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13754777 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13754777 Country of ref document: EP Kind code of ref document: A2 |